Clario

Roche Molecular Systems is a part of Roche Diagnostics Corporation, which produces products based on the polymerase chain reaction technology for molecular diagnostics. The parent company has an on-site laboratory and undertakes research and development activities. Additionally, Roche Diagnostics Corporation undertakes strategic marketing services. Roche Diagnostics Corporation offers a range of diagnostic health care products. The parent company sells the ACCU-CHEK brand of diabetes monitoring equipment and molecular blood screening products. Additionally, Roche Diagnostics Corporation sells the Chemstrip brand of urine test strips. The parent company also sells the Diavant brand of diagnostic products. Roche Diagnostics Corporation offers the Coagucheck brand of anticoagulation testing equipment.

Fisher Clinical Services is one of the leading companies that provides clinical trial supply services in the United States. The company s project managers provide multilingual labeling, inventory control and distribution services. It has in-house tooling design and manufacturing capabilities. The company manufactures overencapsulated supplies for drug blinding purposes. It also offers project management, packaging and logistics services. Fisher Clinical Services is a part of Thermo Fisher Scientific, which provides analytical instruments, equipment, reagents and consumables, as well as software services for research, analysis, discovery and diagnostics purposes. The company more than 30,000 employees and serves over 350,000 customers in pharmaceutical and biotechnological companies, hospitals and clinical diagnostic laboratories, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings.

Bracco, the parent company of Bracco Diagnostics, was founded in 1927. It has been owned and operated for three generations by the Bracco family. The company is an integrated health care group and a world leader in global solutions for the diagnostic imaging field. Born as a pharmaceuticals trading concern, the company has developed an independent industrial production and research activity, specializing its research and development capacities in a specific field - diagnostic imaging. Bracco's laboratories discovered and developed the iopamidol molecule, the first ready-to-use non-ionic contrast medium. In 1994, the company expanded into the United States. It founded Bracco Diagnostics and Bracco Research USA in Princeton, N.J. The United States represents the group's largest market in the sector of contrast agents for medical diagnostics.